These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31221807)

  • 1. King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference.
    Nolan CM; Birring SS; Maddocks M; Maher TM; Patel S; Barker RE; Jones SE; Walsh JA; Wynne SC; George PM; Man WD
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31221807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.
    Sinha A; Patel AS; Siegert RJ; Bajwah S; Maher TM; Renzoni EA; Wells AU; Higginson IJ; Birring SS
    BMJ Open Respir Res; 2019; 6(1):e000363. PubMed ID: 30956799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis.
    Prior TS; Hoyer N; Hilberg O; Shaker SB; Davidsen JR; Bendstrup E
    Respir Res; 2020 Apr; 21(1):91. PubMed ID: 32316976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease.
    Patel AS; Siegert RJ; Bajwah S; Brignall K; Gosker HR; Moxham J; Maher TM; Renzoni EA; Wells AU; Higginson IJ; Birring SS
    J Clin Epidemiol; 2015 Sep; 68(9):1019-27. PubMed ID: 26004514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a Dyspnea Visual Analog Scale in Fibrotic Interstitial Lung Disease.
    Bevanda L; Mok V; Lin K; Assayag D; Fisher JH; Johannson KA; Khalil N; Kolb M; Manganas H; Marcoux V; Sadatsafavi M; Wong AW; Ryerson CJ
    Ann Am Thorac Soc; 2024 Jul; 21(7):1007-1014. PubMed ID: 38315632
    [No Abstract]   [Full Text] [Related]  

  • 6. Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosis.
    Nolan CM; Maddocks M; Maher TM; Canavan JL; Jones SE; Barker RE; Patel S; Jacob J; Cullinan P; Man WD
    Respirology; 2018 May; 23(5):498-506. PubMed ID: 29139195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis.
    Kon SS; Canavan JL; Jones SE; Nolan CM; Clark AL; Dickson MJ; Haselden BM; Polkey MI; Man WD
    Lancet Respir Med; 2014 Mar; 2(3):195-203. PubMed ID: 24621681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.
    Prior TS; Hilberg O; Shaker SB; Davidsen JR; Hoyer N; Birring SS; Bendstrup E
    BMC Pulm Med; 2019 Dec; 19(1):255. PubMed ID: 31856786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.
    Patel AS; Siegert RJ; Keir GJ; Bajwah S; Barker RD; Maher TM; Renzoni EA; Wells AU; Higginson IJ; Birring SS
    Respir Med; 2013 Sep; 107(9):1438-43. PubMed ID: 23867809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes to assess dyspnoea in interstitial lung disease and pulmonary hypertension: a systematic literature review of measurement properties.
    Lemmers JMJ; Vonk MC; van den Ende CHM
    Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36543348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference.
    Kon SS; Dilaver D; Mittal M; Nolan CM; Clark AL; Canavan JL; Jones SE; Polkey MI; Man WD
    Thorax; 2014 Sep; 69(9):793-8. PubMed ID: 24149828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual analogue scales for interstitial lung disease: a prospective validation study.
    Yates H; Adamali HI; Maskell N; Barratt S; Sharp C
    QJM; 2018 Aug; 111(8):531-539. PubMed ID: 29788503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we need a practice incremental shuttle walk test for patients with interstitial lung disease referred for pulmonary rehabilitation?
    Johnson-Warrington V; Sewell L; Morgan M; Singh S
    Respirology; 2015 Apr; 20(3):434-8. PubMed ID: 25615527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism-specific quality of life.
    Akaberi A; Klok FA; Cohn DM; Hirsch A; Granton J; Kahn SR
    J Thromb Haemost; 2018 Dec; 16(12):2454-2461. PubMed ID: 30240543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial.
    Dowman LM; McDonald CF; Hill CJ; Lee AL; Barker K; Boote C; Glaspole I; Goh NSL; Southcott AM; Burge AT; Gillies R; Martin A; Holland AE
    Thorax; 2017 Jul; 72(7):610-619. PubMed ID: 28213592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.
    Birring SS; Bushnell DM; Baldwin M; Mueller H; Male N; Rohr KB; Inoue Y
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34764181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
    Nathan SD; du Bois RM; Albera C; Bradford WZ; Costabel U; Kartashov A; Noble PW; Sahn SA; Valeyre D; Weycker D; King TE
    Respir Med; 2015 Jul; 109(7):914-22. PubMed ID: 25956020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-Repetition Sit-to-Stand Test: Responsiveness and Minimal Important Difference in Idiopathic Pulmonary Fibrosis.
    Trivedi P; Patel S; Edwards G; Jenkins T; Man WD; Nolan CM
    Ann Am Thorac Soc; 2024 Apr; 21(4):577-584. PubMed ID: 37847730
    [No Abstract]   [Full Text] [Related]  

  • 19. Determining the Minimal Clinically Important Difference (MCID) and Responsiveness of the Chinese Version of Zurich Chronic Middle Ear Inventory (ZCMEI-21-Chn): A Prospective Multicenter Study.
    Yang R; Zhang Y; Feng G; Han W; Li Y; Li S; Pan T; Ke J; Zhang K; Xin Y; Song Y; Zuo Q; Zhao Y; Zhou N; Yao Z; Röösli C; Huber AM; Bächinger D; Ma F; Gao Z
    Otol Neurotol; 2024 Aug; 45(7):e532-e540. PubMed ID: 38956761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing health status over time: impact of recall period and anchor question on the minimal clinically important difference of copd health status tools.
    Alma HJ; de Jong C; Jelusic D; Wittmann M; Schuler M; Kollen BJ; Sanderman R; Schultz K; Kocks JWH; Van der Molen T
    Health Qual Life Outcomes; 2018 Jun; 16(1):130. PubMed ID: 29940980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.